Multiple Retinal Artery Occlusions on Anticoagulation – What’s Next?
American Society of Retina Specialists (ASRS) posted on LinkedIn:
”How would you manage a patient with multiple branch retinal artery occlusions despite anticoagulation?
In a new episode of the JVRD Author’s Forum podcast, Dr. Albert Li of Vitreoretinal Consultants of New York joins host Tim Murray to discuss this challenging scenario, featured in the July/August 2025 issue of the Journal of VitreoRetinal Diseases.
Their conversation explores a remarkable case of triple-negative antiphospholipid syndrome in which the patient experienced successive retinal artery occlusions and later died from systemic complications. The discussion highlights:
- The limits of current anticoagulation therapies
- The role of fluorescein angiography and multimodal imaging in diagnosis
- Why urgent, multidisciplinary evaluation is essential for these patients
Watch on YouTube and explore even more episodes at www.ASRS.org/JVRDForum.”
Read the full article here.
Title: Multiple Successive Branch Retinal Artery Occlusions in a Patient With Antiphospholipid Syndrome Despite Anticoagulation
Authors: Samantha R. Goldburg, Albert S. Li
Stay updated with Hemostasis Today.
-
Apr 30, 2026, 18:19Deva Nanda TK: A Practical Overview of Dural Sinuses and The Venous Drainage of the Brain
-
Apr 30, 2026, 18:08Amrit Kaur Kaler: The Hidden Genetic Drivers of Thrombosis
-
Apr 30, 2026, 18:06Alejandro González Veliz: The Most Dangerous Mistake After Getting a Stent
-
Apr 30, 2026, 18:03Carmen Ruiz: First Arterial Mechanical Thrombectomy in New Zealand Using the ARTIX System
-
Apr 30, 2026, 17:52Simon Senanu: von Willebrand Disease May Be Missed Despite Normal Tests
-
Apr 30, 2026, 17:20José Antonio García Erce: Why Healthy Older Adults Should Keep Donating Blood?
-
Apr 30, 2026, 17:13Paul Logan: Decoding the Words ‘He’s on blood thinners’
-
Apr 30, 2026, 17:01Jason Andrade: A Decade-Long Quest Proves Early Ablation Halves Persistent AF Burden
-
Apr 30, 2026, 16:56Oliver Maracic: Could Co-Targeting ALK with FAK/PYK2 Help Mitigate the High VTE Burden Seen in ALK with NSCLC